AI Summary
✦ ClarthaNovelix Pharmaceuticals is an Indian pharmaceutical trading and related-products company. Its revenue activities include pharmaceutical trading, retailing medicines, and marketing services, alongside securities trading. No recent operating development indicates measurable margin or growth improvement; the latest rating remains Hold. Stable margins accompany an 8.0% ROE, while 9.30 debt-to-equity indicates substantial leverage that can inflate reported equity returns. At 63.2 times earnings, the shares appear rich relative to modest profitability and absent disclosed growth. Investor sentiment is neutral, with leverage and limited operating visibility leaving valuation exposed.
Price Forecast
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 53 using EVA spread proxy -4.0%; growth durability 93.7.
Valuation
Valuation institutional score is 0 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
This data source has not been supplied for the decision payload.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 1 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. Available evidence provides partial support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 209.1% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.22). Confidence: 50%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
19.98
Current
63.22
Overvalued
43.83
Undervalued
14.39
5Y Average
14.07
Current
44.51
Overvalued
17.63
Undervalued
5.24
5Y Average
0.52
Current
1.65
Overvalued
0.60
Undervalued
0.44
Peers & Comparison
No sector data available for this company.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹25 CrMar 2026Latest net profit
₹0.91 CrMar 2026Latest EPS
₹0.43Mar 2026Net margin
5.1%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.87 | 1.95 | 0.93 | 0.50 | 0.84 | 0.60 | 3.96 | 5.30 | 20.86 | 22.35 | 36.36 | 48.40 | 25.19 |
| Expenses + | 1.07 | 2.14 | 1.04 | 0.61 | 0.69 | 1.04 | 3.74 | 5.17 | 20.63 | 22.17 | 35.66 | 47.09 | 23.91 |
| Operating Profit | -0.20 | -0.19 | -0.11 | -0.11 | 0.15 | -0.44 | 0.22 | 0.13 | 0.23 | 0.18 | 0.70 | 1.31 | 1.28 |
| OPM % | -22.99% | -9.74% | -11.83% | -22.00% | 17.86% | -73.33% | 5.56% | 2.45% | 1.10% | 0.81% | 1.93% | 2.71% | 5.08% |
| Other Income + | 0.23 | 0.05 | 0.05 | 0.09 | 0.13 | 0.10 | -0.08 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.03 | 0.05 |
| Profit before tax | 0.02 | -0.15 | -0.07 | -0.03 | 0.27 | -0.34 | 0.14 | 0.13 | 0.21 | 0.17 | 0.72 | 1.28 | 1.23 |
| Tax % | 0.00% | 6.67% | 0.00% | 0.00% | 0.00% | 2.94% | 0.00% | -15.38% | 14.29% | 41.18% | 26.39% | 21.88% | 26.02% |
| Net Profit + | 0.01 | -0.17 | -0.07 | -0.03 | 0.28 | -0.35 | 0.13 | 0.15 | 0.18 | 0.11 | 0.53 | 1.00 | 0.91 |
| EPS in Rs | 0.01 | -0.21 | -0.09 | -0.04 | 0.35 | -0.35 | 0.13 | 0.15 | 0.18 | 0.09 | 0.37 | 0.58 | 0.43 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On 13Th August, 2026.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018